HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: M400221-MCP200v1 4/11/1686    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Glossary Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zhang, D. Articles by Koay, E. S. C. Search for Related Content PubMed PubMed Citation Articles by Zhang, D. Articles by Koay, E. S. C. Social Bookmarking                      What's this?

Molecular & Cellular Proteomics 4:1686-1696, 2005.
© 2005 by The American Society for Biochemistry and Molecular Biology, Inc.

---

Research

Proteomic Study Reveals That Proteins Involved in Metabolic and Detoxification Pathways Are Highly Expressed in HER-2/neu-positive Breast Cancer*

DaoHai Zhang, Lee Kian Tai, Lee Lee Wong^¶, Lily-Lily Chiu, Sunil K. Sethi^, and Evelyn S. C. Koay^,,||

From the Department of Laboratory Medicine, National University Hospital, 5 Lower Kent Ridge Road, Singapore 119074, Department of Pathology, National University of Singapore, 10 Kent Ridge Crescent, Singapore 119260, and ^¶ Oncology Research Institute, National University of Singapore, Singapore 117597, Singapore

The receptor tyrosine kinase ErbB2 (HER-2/neu) is overexpressed in up to 30% of breast cancers and is associated with poor prognosis and an increased likelihood of metastasis especially in node-positive tumors. In this proteomic study, to identify the proteins that are associated with the aggressive phenotype of HER-2/neu-positive breast cancer, tumor cells from both HER-2/neu-positive and -negative tumors were procured by laser capture microdissection. Differentially expressed proteins in the two subsets of tumors were identified by two-dimensional electrophoresis and MALDI-TOF/TOF MS/MS. We found differential expression of several key cell cycle modulators, which were linked with increased proliferation of the HER-2/neu-overexpressing cells. Nine proteins involved in glycolysis (triose-phosphate isomerase (TPI), phosphoglycerate kinase 1 (PGK1), and enolase 1 (ENO1)), lipid synthesis (fatty acid synthase (FASN)), stress-mediated chaperonage (heat shock protein 27 (Hsp27)), and antioxidant and detoxification pathways (haptoglobin, aldo-keto reductase (AKR), glyoxalase I (GLO), and prolyl-4-hydrolase ß-isoform (P4HB)) were found to be up-regulated in HER-2/neu-positive breast tumors. HER-2/neu-dependent differential expression of PGK1, FASN, Hsp27, and GLO was further validated in four breast cancer cell lines and 12 breast tumors by immunoblotting and confirmed by partially switching off the HER-2/neu signaling in the high HER-2/neu-expressing SKBr3 cell line with Herceptin treatment. Statistical correlations of these protein expressions with HER-2/neu status were further verified by immunohistochemistry on a tissue microarray comprising 97 breast tumors. Our findings suggest that HER-2/neu signaling may result, directly or indirectly, in enhanced activation of various metabolic, stress-responsive, antioxidative, and detoxification processes within the breast tumor microenvironment. We hypothesize that these identified changes in the cellular proteome are likely to drive cell proliferation and tissue invasion and that the key cell cycle modulators involved, when uncovered by future research, would serve as naturally useful targets for the development of therapeutic strategies to negate the metastatic potential of HER-2/neu-positive breast tumors.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				H. Pang, D. Datta, and H. Zhao Pathway analysis using random forests with bivariate node-split for survival outcomes Bioinformatics, January 15, 2010; 26(2): 250 - 258. [Abstract] [Full Text] [PDF]

				C. V. Recktenwald, R. Kellner, R. Lichtenfels, and B. Seliger Altered Detoxification Status and Increased Resistance to Oxidative Stress by K-Ras Transformation Cancer Res., December 15, 2008; 68(24): 10086 - 10093. [Abstract] [Full Text] [PDF]

				I. I. Daud and M. E. Scott Validation of Reference Genes in Cervical Cell Samples from Human Papillomavirus-Infected and -Uninfected Women for Quantitative Reverse Transcription-PCR Assays Clin. Vaccine Immunol., September 1, 2008; 15(9): 1369 - 1373. [Abstract] [Full Text] [PDF]

				R. J. Gillies, I. Robey, and R. A. Gatenby Causes and Consequences of Increased Glucose Metabolism of Cancers J. Nucl. Med., June 1, 2008; 49(Suppl_2): 24S - 42S. [Abstract] [Full Text] [PDF]

				J. Ursini-Siegel, A. B. Rajput, H. Lu, V. Sanguin-Gendreau, D. Zuo, V. Papavasiliou, C. Lavoie, J. Turpin, K. Cianflone, D. G. Huntsman, et al. Elevated Expression of DecR1 Impairs ErbB2/Neu-Induced Mammary Tumor Development Mol. Cell. Biol., September 15, 2007; 27(18): 6361 - 6371. [Abstract] [Full Text] [PDF]

				W. Lam, C.-H. Leung, S. Bussom, and Y.-C. Cheng The Impact of Hypoxic Treatment on the Expression of Phosphoglycerate Kinase and the Cytotoxicity of Troxacitabine and Gemcitabine Mol. Pharmacol., September 1, 2007; 72(3): 536 - 544. [Abstract] [Full Text] [PDF]

				J. Wang, J. Wang, J. Dai, Y. Jung, C.-L. Wei, Y. Wang, A. M. Havens, P. J. Hogg, E. T. Keller, K. J. Pienta, et al. A Glycolytic Mechanism Regulating an Angiogenic Switch in Prostate Cancer Cancer Res., January 1, 2007; 67(1): 149 - 159. [Abstract] [Full Text] [PDF]

				N. S. Azad, N. Rasool, C. M. Annunziata, L. Minasian, G. Whiteley, and E. C. Kohn Proteomics in Clinical Trials and Practice: Present Uses and Future Promise Mol. Cell. Proteomics, October 1, 2006; 5(10): 1819 - 1829. [Abstract] [Full Text] [PDF]

				R. Lupu and J. A. Menendez Targeting Fatty Acid Synthase in Breast and Endometrial Cancer: An Alternative to Selective Estrogen Receptor Modulators? Endocrinology, September 1, 2006; 147(9): 4056 - 4066. [Abstract] [Full Text] [PDF]

				F. P. Kuhajda Fatty Acid synthase and cancer: new application of an old pathway. Cancer Res., June 15, 2006; 66(12): 5977 - 5980. [Abstract] [Full Text] [PDF]

				J. A. Menendez and R. Lupu RESPONSE: Re: Effect of {gamma}-Linolenic Acid on the Transcriptional Activity of the Her-2/neu (erbB-2) Oncogene J Natl Cancer Inst, May 17, 2006; 98(10): 718 - 720. [Full Text] [PDF]